Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 37 articles:
HTML format

Single Articles

    September 2022
  1. RADES D, Kopelke S, Schild SE, Kjaer TW, et al
    Evaluation of Sleep Disturbances in Patients With Bladder Cancer Scheduled for Local or Loco-regional Radiochemotherapy.
    Anticancer Res. 2022;42:4511-4515.
    PubMed     Abstract available

    August 2022
  2. VASSILIOU V, Katsila T, Sodergren SC, Kardamakis D, et al
    Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications.
    Anticancer Res. 2022;42:3767-3778.
    PubMed     Abstract available

    July 2022
  3. INOUE S, Sassa N, Kawanishi H, Yuguchi Y, et al
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Anticancer Res. 2022;42:3627-3636.
    PubMed     Abstract available

  4. DENG F, Kong MX, Lai J
    Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
    Anticancer Res. 2022;42:3601-3605.
    PubMed     Abstract available

  5. WALLACE B, Dekalo S, Kabha M, Mintz I, et al
    Can We Predict a Higher Risk of Urothelial Bladder Cancer With a Simple Blood Test?
    Anticancer Res. 2022;42:3569-3573.
    PubMed     Abstract available

    March 2022
  6. TOMISAKI I, Harada M, Minato A, Nagata Y, et al
    Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Anticancer Res. 2022;42:1629-1634.
    PubMed     Abstract available

  7. FURUBAYASHI N, Morokuma F, Tomoda T, Hori Y, et al
    Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Anticancer Res. 2022;42:1571-1577.
    PubMed     Abstract available

  8. SALKINI MW, Yang X, Hashmi FH, Kandzari SJ, et al
    First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report.
    Anticancer Res. 2022;42:1339-1344.
    PubMed     Abstract available

    February 2022
  9. KURASHINA R, Ando K, Inoue M, Izumi K, et al
    Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
    Anticancer Res. 2022;42:1131-1136.
    PubMed     Abstract available

    January 2022
  10. KACZOROWSKI M, Matysiak J, Kielb P, Malkiewicz B, et al
    Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers.
    Anticancer Res. 2022;42:493-500.
    PubMed     Abstract available

    December 2021
  11. WONG BS, Wu WT, Su JH, Goan YG, et al
    Flaccidoxide Induces Apoptosis Through Down-regulation of PI3K/AKT/mTOR/p70S6K Signaling in Human Bladder Cancer Cells.
    Anticancer Res. 2021;41:6123-6133.
    PubMed     Abstract available

  12. OKUBO K, REssING N, Schulz WA, Hansen FK, et al
    The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
    Anticancer Res. 2021;41:5987-5996.
    PubMed     Abstract available

    November 2021
  13. YUMIOKA T, Honda M, Shimizu R, Teraoka S, et al
    Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
    Anticancer Res. 2021;41:5767-5773.
    PubMed     Abstract available

  14. PALACKA P, Slopovsky J, Obertova J, Chovanec M, et al
    Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Anticancer Res. 2021;41:5749-5759.
    PubMed     Abstract available

  15. FISCHER N, Ellinger J, Koeditz B, Heidenreich A, et al
    Predictors for Outcome and Complications Related to Urinary Diversion.
    Anticancer Res. 2021;41:5585-5591.
    PubMed     Abstract available

    October 2021
  16. PAN Y, Hong YC, Hsiao CH, Shih HJ, et al
    Effects of Concurrent Chemoradiotherapy on the Metastasis and the Mesenchymal Transition of Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2021;41:4957-4968.
    PubMed     Abstract available

    August 2021
  17. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    PubMed     Abstract available

  18. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    PubMed     Abstract available

  19. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    PubMed     Abstract available

  20. MATSUNAGA W, Hamada K, Tagawa M, Morinaga T, et al
    Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector.
    Anticancer Res. 2021;41:3731-3740.
    PubMed     Abstract available

    June 2021
  21. OKUBO K, Isono M, Asano T, REssING N, et al
    Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Anticancer Res. 2021;41:2901-2912.
    PubMed     Abstract available

    May 2021
  22. XIAO H, Alisic H, Reiman BT, Deng Z, et al
    IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas.
    Anticancer Res. 2021;41:2239-2245.
    PubMed     Abstract available

    December 2020
  23. ADELMANN TG, Camerota TC, Ceausu AR, Cimpean AM, et al
    Chloride Intracellular Channel Protein 1 (CLIC1) Iotas Over-expressed in Muscle Invasive Urinary Bladder Cancer.
    Anticancer Res. 2020;40:6879-6884.
    PubMed     Abstract available

    November 2020
  24. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Anticancer Res. 2020;40:6093-6099.
    PubMed     Abstract available

  25. SUN YU, Nishino H, Sugisawa N, Yamamoto J, et al
    Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis.
    Anticancer Res. 2020;40:6083-6091.
    PubMed     Abstract available

    October 2020
  26. MAJEWSKI W, Nieckula J, Dworzecki T, Miszczyk L, et al
    Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer - A Single-institution Experience.
    Anticancer Res. 2020;40:5861-5868.
    PubMed     Abstract available

    September 2020
  27. YAMAMOTO S, Kageyama Y, Fujii Y, Aizawa T, et al
    Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer.
    Anticancer Res. 2020;40:5295-5299.
    PubMed     Abstract available

  28. PAN Y, Chiu YH, Chiu SC, Cho DY, et al
    Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells.
    Anticancer Res. 2020;40:5221-5227.
    PubMed     Abstract available

    August 2020
  29. HAGA N, Tsubouchi K, Maruta H, Koguchi T, et al
    Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor.
    Anticancer Res. 2020;40:4299-4307.
    PubMed     Abstract available

  30. TAKEMOTO K, Teishima J, Kohada Y, Ikeda K, et al
    The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Anticancer Res. 2020;40:4787-4793.
    PubMed     Abstract available

    July 2020
  31. BARAK V, Itzkovich D, Einarsson R, Gofrit O, et al
    Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology.
    Anticancer Res. 2020;40:3967-3972.
    PubMed     Abstract available

    May 2020
  32. ADACHI A, Kawamura H, Yoshida D, Kawahara M, et al
    Whole-bladder Radiation Therapy for Lymph Node-negative Bladder Cancer With Muscle Invasion in Elderly Patients.
    Anticancer Res. 2020;40:2905-2909.
    PubMed     Abstract available

  33. HUANG CP, Liu LX, Shyr CR
    Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression.
    Anticancer Res. 2020;40:2715-2724.
    PubMed     Abstract available

    April 2020
  34. CHEN M, Chang WS, Shen TC, Gong CL, et al
    Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2020;40:2011-2017.
    PubMed     Abstract available

    March 2020
  35. YU J, Lu Y, Muto S, Ide H, et al
    The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis.
    Anticancer Res. 2020;40:1345-1357.
    PubMed     Abstract available

    December 2019
  36. LIU J, Li S, Cheng X, DU P, et al
    HOXB2 is a Putative Tumour Promotor in Human Bladder Cancer.
    Anticancer Res. 2019;39:6915-6921.
    PubMed     Abstract available

  37. LEE MY, Shi CS, Hsu YC, Huang KJ, et al
    Honokiol Is a Potential Therapeutic Agent and Has a Synergistic Effect With 5-FU in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2019;39:6555-6565.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.